Advertisement
Advertisement
TOPIC
 / company

Macquarie

Macquarie
The latest news and top stories on Macquarie. A leading entity in the financial services sector, Sydney Australia based Macquarie is a global investment banking and financial services group. They specialise in asset management, retail and business banking, wealth management, and advisory services, serving government institutional corporate and retail clients worldwide. Known as one of the world’s largest infrastructure asset managers and a global specialist in renewables and commodities, Macquarie’s overall business focus is on providing diversified financial solutions. Larry Hu serves as its chief China economist.
Asset id: 2156561481 Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock Images
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Hong Kong

China’s pharma contractors rally on pushback to US supply chain pressure

China economy

Opinion | How likely is Beijing to walk the talk on boosting consumption?

China’s private sector

What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?

Analysts say that China’s pivot from generics to innovative drugs means the industry is less exposed to US levies.

videocam
16
A production line of capsule package. Photo: Getty Images
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
China’s private sector

Europe beckons: can Chinese medical device makers thrive amid trade barriers?

Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.

Advertisement
Advertisement
Advertisement
China consumption

China faces economic balancing act: AI, exports boom while consumers stay home

Two high-level meetings show that Beijing is aware of economic imbalances as Politburo prepares high-stakes growth assessment next month.

A shopping mall in Shanghai. In a bid to avoid economic divergence, China is looking to boost domestic consumption amid weakened domestic demand. Photo: EPA
Fifa

Fifa World Cup tipped to be ‘biggest betting event of all’, with US$50b at stake

Big jump forecast in betting volumes compared with 2022 World Cup as match times, North American hosts prove a boon for betting firms.

China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Hong Kong stock market

Lenovo targets US$2b bond to repurchase debt amid AI infrastructure growth

World’s largest PC maker plans to use the proceeds to buy back shares and strengthen its financial position amid sustained growth.

Lenovo plans to raise US$2 billion through a convertible-bond offering, according to a filing it made to the Hong Kong stock exchange on Thursday. Photo: Jelly Tse
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Banking & finance

AI | AI infrastructure investment bubble unlikely to burst by 2027: Macquarie

Investors are piling money into AI technologies – but revenues still have a long way to catch up, Macquarie’s Viktor Shvets says.

Artificial intelligence

China’s booming tech exports give Beijing ‘wind in its sails’ for Trump summit

The role of tech products in April’s trade data reflects how computing-related goods are a ‘new and important growth driver’ for exports.

24
Chinese trade received a significant boost from the technology sector in April. Photo: Shutterstock Images
Japan

Bound by anxiety: Japan and Australia deepen ties for an uneasy age

Shared concerns about trade coercion and energy shocks are driving the two middle powers to ‘institutionalise’ their partnership.

Japanese Prime Minister Sanae Takaichi and Australian Prime Minister Anthony Albanese at the signing of their Joint Declaration on Economic Security Cooperation in Canberra on Monday. Photo: AAP/dpa
China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Advertisement
Advertisement
Advertisement
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
US-China trade war

Why Trump pushing China to help reopen the Strait of Hormuz may hurt trade talks

US president’s threat to delay summit with Xi adds uncertainty to Paris negotiations, analysts say.

videocam
19
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
China’s private sector

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.

Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Chinese culture

Language Matters | Word of the Year 2025 choices reflect how virtual our reality has become

From Oxford’s ‘rage bait’ to Macquarie Dictionary’s ‘AI slop’, 2025 WOTYs show the influence of the virtual world on our daily lives.

Word of the Year 2025 choices around the world – including Oxford’s “rage bait” and Cambridge Dictionary’s “parasocial” – reflect the increasing influence that artificial intelligence has on everyday life. Photo: Shutterstock
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Hong Kong Monetary Authority (HKMA)

Exclusive | From boardrooms to hiking trails: HKMA courts top bankers with business and leisure

BlackRock’s Larry Fink and General Atlantic’s William Ford will attend the HKMA summit for the first-time.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement